NTRK1 and non-small cell lung carcinoma: In contrast, non-small cell lung cancer (NSCLC) is characterized by activating mutations affecting proto-oncogenic receptor tyrosine kinases or downstream signal transducers, offering personalized therapy options with oncogene-targeted drugs such as tyrosine or MAP kinase inhibitors [2].